E-GEOD-39413 - Regulation of gene expressions in vivo by anti-VEGF and anti-Notch therapy [Mouse430_2]

Released on 25 April 2014, last updated on 2 June 2014
Homo sapiens
Samples (14)
Array (1)
Protocols (7)
U87-EV human glioblastoma xenograft tumours is therapeutically treated by bevacizumab, a humanized anti-human VEGF mAb, or dibenzazepine (DBZ) when tumour is established in BALB/c SCID mice. At the end point, collect tumour samples and extracted total RNA for microarray to investigate the gene profile changes compared to control. These include the genes from human tumour cells and mouse host stroma cells. 5 control, 5 dibenzazepine-treated, and 4 bevacizumab-treated samples
Experiment type
transcription profiling by array 
A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Masiero M, Sim�es FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, Han C, Dalton H, Lopez-Berestein G, Tuynman JB, Mortensen N, Li JL, Patient R, Sood AK, Banham AH, Harris AL, Buffa FM. , Europe PMC 23871637
Investigation descriptionE-GEOD-39413.idf.txt
Sample and data relationshipE-GEOD-39413.sdrf.txt
Raw data (1)E-GEOD-39413.raw.1.zip
Processed data (1)E-GEOD-39413.processed.1.zip
Array designA-AFFY-45.adf.txt